Recent Updates
Recently added Catalysts

ARO-MAPT

Phase 1/2

Alzheimer Disease | RNA-Based Therapies | Neurology |Arrowhead Pharmaceuticals, Inc.|Trials Updated: Nov 10, 2026

ARO-MAPT target and mechanism

Molecular targetMAPT
ModalityRNA-Based Therapies

Also known as ARO-MAPT-SC

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment160

FDA Designations

No designations recorded

ARO-MAPT clinical trials

ARO-MAPT · 1 trial · 4 indications

Phase 1/2 1
NCT07221344Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary TauopathiesAlzheimer Disease
RECRUITING160 Analytics
PHASE1/PHASE2RECRUITING
Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies
Alzheimer DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Treatment-emergent Adverse Events (TEAEs) Over Time
Through End of Trial (EOT; up to a maximum of Day 375)

Secondary Endpoints

PK of ARO-MAPT-SC: Maximum Observed Plasma Concentration (Cmax)
Through a maximum of 192 hours postdose
PK of ARO-MAPT-SC: Time to Maximum Plasma Concentration (Tmax)
Through a maximum of 192 hours postdose
PK of ARO-MAPT-SC: Area Under the Plasma Concentration (AUC) Versus Time Curve From Time Zero to 24 Hours (AUC0-24)
Through 24 hours postdose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ARO-MAPT-SCEXPERIMENTALARO-MAPT-SC injection
PlaceboPLACEBO_COMPARATORSterile normal saline (0.9%)

Interventions

NameTypeDescription
ARO-MAPT-SCDRUG• single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection
PlaceboDRUG• calculated volume to match active treatment by SC administration
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites4

Inclusion Criteria (All Participants): * Body mass index between 18.0 and 35.0 kilograms (kg)/square meter (m\^2) at Screening * Not pregnant or breast-feeding * Able and willing to provide written informed consent prior to the performance of any trial specific procedures * Participants of childbea...

Countries:CanadaNew Zealand
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 10, 2026NCT07221344Enrollment: 112 → 160
LOWSep 19, 2026NCT07221344Record updated: Jun 23, 2026 → Sep 18, 2026

Frequently asked questions about ARO-MAPT

What is ARO-MAPT used for?

ARO-MAPT is an investigational RNA-based therapy being developed for Alzheimer disease. It is also being studied in primary tauopathies, including frontotemporal dementia and progressive supranuclear palsy. It is in Phase 1/2 clinical development and is not approved for any use.

What does ARO-MAPT target?

ARO-MAPT targets MAPT, the gene that encodes tau protein. As an RNA-based therapy, it is designed to act on MAPT RNA. The Phase 1/2 trial enrolls healthy participants and participants with early Alzheimer disease or primary tauopathies.

Who is developing ARO-MAPT?

ARO-MAPT is being developed by Arrowhead Pharmaceuticals, Inc., which trades on Nasdaq under the ticker ARWR. The company is running the program as an RNA-based therapy in its neurology portfolio, with Alzheimer disease as the lead indication.

What phase is ARO-MAPT in?

ARO-MAPT is in Phase 1/2 clinical development. It is investigational and has not been approved by the FDA or any other regulator. The single active trial is a combined Phase 1/Phase 2 study that is currently recruiting participants.

What clinical trials is ARO-MAPT in?

ARO-MAPT is being studied in trial NCT07221344, titled a trial of ARO-MAPT-SC in healthy participants and participants with early Alzheimer's disease or primary tauopathies. The trial is recruiting, is placebo-controlled and double-blind, and plans to enroll 160 participants across Canada and New Zealand.

Is ARO-MAPT the same as ARO-MAPT-SC?

Yes, ARO-MAPT-SC is another name for ARO-MAPT. The Phase 1/2 trial NCT07221344 uses the ARO-MAPT-SC designation in its title, and both names refer to the same investigational RNA-based therapy targeting MAPT being developed by Arrowhead Pharmaceuticals.